Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation.
暂无分享,去创建一个
S. Mineishi | Y. Kanda | K. Tobinai | A. Saito | H. Kunitoh | A. Makimoto | Y. Takaue | R. Tanosaki | Takeshi Saito | H. Matsubara | K. Nakai | A. Chizuka | H. Niiya | M. Ohnishi | T. Takeuchi
[1] S. Mineishi,et al. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. , 2001, Blood.
[2] S. Mineishi,et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan , 2001, Bone Marrow Transplantation.
[3] A. Limaye,et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.
[4] R. Osarogiagbon,et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] Y. Morishima,et al. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors. , 1999, International journal of hematology.
[6] M. Boeckh,et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. , 1999, Blood.
[7] S. Brunet,et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience , 1998, Bone Marrow Transplantation.
[8] L. Verdonck,et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. , 1997, Clinical Infectious Diseases.
[9] M. Boeckh,et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.
[10] S. Forman,et al. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? [see comments] , 1994 .
[11] K. Akashi,et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation , 1994, British journal of haematology.
[12] G. Schoch,et al. Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant , 1993, Annals of Internal Medicine.
[13] R. Champlin,et al. Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind Trial , 1993, Annals of Internal Medicine.
[14] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[15] W. V. van Son,et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes , 1988, Journal of medical virology.
[16] T. Hibi,et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.
[17] Y. Yazaki,et al. Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. , 1998, British journal of haematology.
[18] K. St. George,et al. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy. , 1997, Journal of pediatric hematology/oncology.